Climb Bio Inc (CLYM) Historical Volatility

Tracking CLYM historical volatility helps you see how much Climb Bio Inc's stock price has actually moved over past periods, giving you a baseline to judge whether current option premiums are fair, cheap, or expensive. While implied volatility tells you what the market expects, Climb Bio Inc's HV tells you what really happened. Use our scanner to monitor CLYM 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of an underlying's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. The CLYM 30 day historical volatility is one of the most widely watched readings because it balances responsiveness with stability. Comparing Climb Bio Inc's HV to its implied volatility reveals the volatility risk premium — when IV sits well above HV, option sellers tend to have an edge; when HV runs hot relative to IV, buyers may be underpaying for movement.

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Sizing a long premium trade, modeling a covered call, or hunting volatility arbitrage all come back to one question: how much has the stock actually moved? Our scanner puts Climb Bio Inc's historical volatility side-by-side with implied readings across every lookback window, so you can see exactly where CLYM HV is running hot, cold, or in line. Make the CLYM 30 day historical volatility — and every other window — work for your edge instead of against it.